The variation seen between different IDC patients with more or less severe HEV remodeling and with different degree of stromal functional disruption, with and without accumulation of CCL21 on lymphocytes, is likely to influence their ability to induce effective anti-tumor responses. The gene discussed is CCL21; the disease is neoplasm.